Table D14. Medication adherence outcomes 6

| Author, Year  Trial name | Medication Adherence Outcome 6 | Description of Timing of Measurement of Adherence Outcome 6 | Data Source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Hoffman et al., 200318 NA | Persistency (defined as the time span a patient continued taking the antidepressant prescription during the study. If the date of the last prescription filled plus the days’ supply was ≤10 days from the end of the study, the patient was considered to be persistent) | Measured for previous 30 days, at 2, 3, 4, 5, and 6 months | PRD | G1: 4889  G2: 4665 | **At 2 months**: G1: 45.9 G2: 44.3 **At 3 months:** G1: 36.8 G2: 35.3 **At 4 months:** G1: 30.2 G2: 28.9 **At 5 months**: G1: 28.8 G2: 27.3 **At 6 months:** G1: 24.9 G2: 23.4 95%Cis & p: NR  **From 1-90 days**: Mean percent (SD):  G1: 36.8 (24.3) G2: 35.3 (12.4) Chi-square: 0.127 95% CI, NR p: NR  **From 1-180 days**: Mean percent (SD):  G1: 24.9 (51.9) G2: 23.3 (51.9) Chi-square: 0.067 95% CI, NR p: NR |
| Murray et al., 200736 NA | Self-reported adherence from questionnaire at baseline and 9 month to compute a composite score of self-reported adherence | Measured at 1 month prior to intervention (baseline) and at month 9 | Self-report | G1: NR G2: NR | G1: 1.0 G2: 0.8 95% CI, NR  p: 0.48 |
| Pyne et al., 201141 HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | antidepressant prescription rates (of providers) at 12 months | Not clear whether self-report or other method. 3 measurements taken: baseline, 6-month and 12-months. | Other | G1: 65/105 (61.9) G2: 69/110 (62.7) | G1: 65/105 (61.9) G2: 69/110 (62.7), OR: 0.93 (0.49-1.78); adjusted OR: 0.93 (0.49-1.78) Adjusted p: 0.93 |
| Stacy et al., 200956 NA | 6 month point prevalence persistency: subject being in possession of a statin at the end of the 180-day observation period (For those with continuous persistance + MPR=>80%) | 6 months after baseline; 1 time; N/A | PRD | Overall N:NR SG1: NR SG2: NR | SG1: 25.9% SG2: 3.3% 95% CI, NR p: <0.05 |
| Vivian et al., 200258 NA | % that received refills for antihypertensive agents within 2 weeks of the next scheduled refill date | NR | PRD | G1: 26 G2: 27 | G1: 85%  G2: 93% 95% CI, NR p: >0.42 |
| Wilson et al., 201065 Better Outcomes of Asthma Treatment (BOAT) | Medication acquisition at Year 1 and Year 2 -for long-acting beta agonists (LABA) Fill/reﬁll adherence was measured using a continuous medication acquisition (CMA) index for each year, calculated as the total days’ supply acquired in a given year divided by 365 days | Measured as aggregate for year; at Year-1 follow-up and Year 2 follow-up | PRD | N for Year 1: G1: 40 G2: 44 G3: 52  N for Year 2: G1:112 G2: 108 G3:59 | Group differences YEAR 1: G1-G3: 0.11 95% CI, 0.02 to 0.20 G1-G2: 0.09 95% CI, 0.02 to 0.17 G2-G3: 0.01  95% CI, -0.08 to 0.11 YEAR 2:  G1-G3: 0.11 95% CI, 0.01 to 0.20 G1:G2: 0.09 95% CI, 0.01 to 0.18 G2-G3: 0.01 95% CI, -0.08 to 0.11 |